Mutations of the CFTR gene and novel variants in Turkish patients with cystic fibrosis: 24-years experience

被引:5
作者
Dayangac-Erden, Didem [1 ]
Atalay, Merve [1 ]
Emiralioglu, Nagehan [2 ]
Hizal, Mina [2 ]
Polat, Sanem [2 ]
Ozcelik, Ugur [2 ]
Yalcin, Ebru [2 ]
Dogru, Deniz [2 ]
Yilmaz, Engin [1 ]
Kiper, Nural [2 ]
机构
[1] Hacettepe Univ, Dept Med Biol, Fac Med, Rectorate Bldg A, TR-06100 Ankara, Turkey
[2] Hacettepe Univ, Dept Pediat Pulmonol, Fac Med, Ankara, Turkey
关键词
Cystic fibrosis; Genetic screening; Novel variants; In silico analysis; Genotype- phenotype correlation; Personalized medicine;
D O I
10.1016/j.cca.2020.07.033
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Cystic fibrosis, the most prevalent autosomal recessive genetic disease, is caused by mutations in the CFTR gene. The spectrum and frequency of CFTR mutations in Turkish patients show heterogeneity. Methods: We investigated CFTR gene mutations in samples from 604 cystic fibrosis patients diagnosed at Hacettepe University, the largest referral CF center in Turkey, by different techniques such as strip assay and direct sequencing. We also analyzed the effects of novel variants and predicted pathogenicity by integrating information from different insilico tools. Results: We showed that mutation detection rate increased to 76.7% with direct sequencing of the coding region and exon/intron boundaries. Ten variants were described for the first time. All variants except T788R were reported as pathogenic. Conclusion: Characterization of patients with CFTR mutations that occur at very low frequencies is necessary for mutation-based treatments. Population specific genetic screening panels should be designed since none of them are suitable for Turkish patients due to heterogeneous mutation distribution. The preliminary data obtained from in silico results of novel variants will pave the way for functional analysis by using samples obtained from patients. These observations will facilitate the discovery and development of new targeted and personalized therapies.
引用
收藏
页码:252 / 259
页数:8
相关论文
共 24 条
[1]   Novel mutations and deletions in cystic fibrosis in a tertiary cystic fibrosis center in Istanbul [J].
Atag, Emine ;
Ikizoglu, Nilay Bas ;
Ergenekon, Almala Pinar ;
Gokdemir, Yasemin ;
Eralp, Ela Erdem ;
Ata, Pinar ;
Ersu, Refika ;
Karakoc, Fazilet ;
Karadag, Bulent .
PEDIATRIC PULMONOLOGY, 2019, 54 (06) :743-750
[2]   CFTR regulatory region interacts with NBD1 predominantly via multiple transient helices [J].
Baker, Jennifer M. R. ;
Hudson, Rhea P. ;
Kanelis, Voula ;
Choy, Wing-Yiu ;
Thibodeau, Patrick H. ;
Thomas, Philip J. ;
Forman-Kay, Julie D. .
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2007, 14 (08) :738-745
[3]   Cystic fibrosis: A worldwide analysis of CFTR mutations - Correlation with incidence data and application to screening [J].
Bobadilla, JL ;
Macek, M ;
Fine, JP ;
Farrell, PM .
HUMAN MUTATION, 2002, 19 (06) :575-606
[4]   Nonclassic cystic fibrosis and CFTR-related diseases [J].
Boyle, MP .
CURRENT OPINION IN PULMONARY MEDICINE, 2003, 9 (06) :498-503
[5]  
Çankaya T, 2015, MINERVA PEDIATR, V67, P407
[6]   Cystic fibrosis genetics: from molecular understanding to clinical application [J].
Cutting, Garry R. .
NATURE REVIEWS GENETICS, 2015, 16 (01) :45-56
[7]   Cystic fibrosis in Turkey: First data from the national registry [J].
Dogru, Deniz ;
Cakir, Erkan ;
Sismanlar, Tugba ;
Cobanoglu, Nazan ;
Pekcan, Sevgi ;
Cinel, Guzin ;
Yalcin, Ebru ;
Kiper, Nural ;
Sen, Velat ;
Sen, Hadice S. ;
Ercan, Omur ;
Keskin, Ozlem ;
Eltan, Sevgi B. ;
Al Shadfan, Lina M. ;
Yazan, Hakan ;
Altintas, Derya U. ;
Sasihuseyinoglu, Senay ;
Sapan, Nihat ;
Cekic, Sukru ;
Cokugras, Haluk ;
Kilinc, Ayse A. ;
Gursoy, Tugba R. ;
Aslan, Ayse T. ;
Bingol, Aysen ;
Basaran, Abdurrahman E. ;
Ozdemir, Ali ;
Kose, Mehmet ;
Hangul, Melih ;
Emiralioglu, Nagehan ;
Tugcu, Gokcen ;
Yuksel, Hasan ;
Yilmaz, Ozge ;
Orhan, Fazil ;
Gayretli Aydin, Zeynep G. ;
Topal, Erdem ;
Tamay, Zeynep ;
Suleyman, Ayse ;
Can, Demet ;
Bal, Cem M. ;
Caltepe, Gonul ;
Ozcelik, Ugur .
PEDIATRIC PULMONOLOGY, 2020, 55 (02) :541-548
[8]   Assessing the Disease-Liability of Mutations in CFTR [J].
Ferec, Claude ;
Cutting, Garry R. .
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2012, 2 (12)
[9]  
GURSON CT, 1973, HELV PAEDIATR ACTA, V28, P165
[10]   Highest heterogeneity for cystic fibrosis:: 36 mutations account for 75% of all CF chromosomes in Turkish patients [J].
Kilinc, MO ;
Ninis, VN ;
Dagli, E ;
Demirkol, M ;
Özkinay, F ;
Arikan, Z ;
Çogulu, Ö ;
Hüner, G ;
Karakoç, F ;
Tolun, A .
AMERICAN JOURNAL OF MEDICAL GENETICS, 2002, 113 (03) :250-257